U.S. News Room
December 22, 2025
ENHERTU Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Download
December 22, 2025
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Download
December 15, 2025
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
December 09, 2025
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Download